FDA expands approval of Blinatumomab for treatment of a type of leukemia in patients who have a certain risk factor for relapse

March 29, 2018 – The U.S. Food and Drug Administration granted accelerated approval to Blinatumomab to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved remission after initial treatment for this type of ALL, the presence of MRD means they … (leggi tutto)